Open Access

Claudia Traidl‐Hoffmann, Jamie Afghani, Cezmi Akdis, Mübecel Akdis, Handan Aydin, Katja Bärenfaller, Heidrun Behrendt, Thomas Bieber, Paul Bigliardi, Mei Bigliardi‐Qi, Charlotte Menné Bonefeld, Stefanie Bösch, Marie Charlotte Brüggen, Sebastian Diemert, Hans‐Werner Duchna, Martina Fähndrich, Danielle Fehr, Marc Fellmann, Remo Frei, Lena H. Garvey, Raschid Gharbo, Mehmet Gökkaya, Karin Grando, Carole Guillet, Erman Guler, Jan Gutermuth, Nadine Herrmann, Dirk Jan Hijnen, Claudia Hülpüsch, Alan D. Irvine, Erika Jensen‐Jarolim, Heidi H. Kong, Hillel Koren, Claudia C. V. Lang, Roger Lauener, Laura Maintz, Pierre‐Yves Mantel, Emanuel Maverakis, Matthias Möhrenschlager, Svenja Müller, Kari Nadeau, Avidan U. Neumann, Liam O'Mahony, Fahafahantsoa Rapelanoro Rabenja, Harald Renz, Claudio Rhyner, Ernst Rietschel, Johannes Ring, Caroline Roduit, Mari Sasaki, Mirjam Schenk, Jens Schröder, Dagmar Simon, Hans‐Uwe Simon, Milena Sokolowska, Sonja Ständer, Martin Steinhoff, Doris Straub Piccirillo, Alain Taïeb, Roberto Takaoka, Martin Tapparo, Henrique Teixeira, Jacob Pontoppidan Thyssen, Stephan Traidl, Miriam Uhlmann, Willem van de Veen, Marianne van Hage, Christian Virchow, Andreas Wollenberg, Mitamura Yasutaka, Alexander Zink, Peter Schmid‐Grendelmeier

• The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized aThe 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.…